An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants With Grade 3/Grade 4 Laboratory Test Results

  Measured over: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)

• Number of Participants With Adverse Events and Deaths

  Measured over: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)

• Number of Participants With Dose Limiting Toxicities

  Measured over: From first dose (Day 1) and up to 42 days post first dose

• Objective Response Rate (ORR)

  Measured over: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

• Disease Control Rate (DCR)

  Measured over: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

• Duration of Response (DoR)

  Measured over: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)

Changes Tremor has spotted